Natco Pharma share news and announcements
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Last close ₹791.85up ₹6.70 (0.85%)BSE ₹792.20
Share price at the NSE close on 23 Oct 2026. Previous close ₹785.15.
52-week range of traded prices to 23 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,534 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 13.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 5,69,53550.8% delivered
Natco Pharma routine notices
195 filed, newest first. Page 3 of 4.
Mar 2023
17 Mar · Routine
Feb 2023
27 Feb · Routine
23 Feb · Routine
10 Feb · Routine
7 Feb · Routine
Jan 2023
19 Jan · Routine
11 Jan · Routine
Dec 2022
28 Dec · Routine
3 Dec · Routine
Nov 2022
23 Nov · Routine
15 Nov · Routine
1 Nov · Routine
Oct 2022
14 Oct · Routine
Sep 2022
16 Sep · Routine
Aug 2022
Jul 2022
2 Jul · Routine
Jun 2022
30 Jun · Routine
May 2022
25 May · Routine
5 May · Routine
4 May · Routine
Apr 2022
14 Apr · Routine
Mar 2022
31 Mar · Routine
23 Mar · Routine
3 Mar · Routine
Feb 2022
15 Feb · Routine
1 Feb · Routine
Jan 2022
14 Jan · Routine
14 Jan · Routine
Dec 2021
29 Dec · Routine
13 Dec · Routine
Nov 2021
22 Nov · Routine
16 Nov · Routine
12 Nov · Routine
Oct 2021
26 Oct · Routine
Sep 2021
30 Sep · Routine
3 Sep · Routine